Compare · ABBV vs PHAT
ABBV vs PHAT
Side-by-side comparison of AbbVie Inc. (ABBV) and Phathom Pharmaceuticals Inc. (PHAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and PHAT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $401.47B, about 496.9x PHAT ($807.9M).
- Over the past year, ABBV is up 20.1% and PHAT is up 14.6% - ABBV leads by 5.6 points.
- PHAT has been more active in the news (11 items in the past 4 weeks vs 10 for ABBV).
- ABBV has more recent analyst coverage (25 ratings vs 11 for PHAT).
- Company
- AbbVie Inc.
- Phathom Pharmaceuticals Inc.
- Price
- $227.09+0.98%
- $10.14+3.05%
- Market cap
- $401.47B
- $807.9M
- 1M return
- +10.76%
- -19.97%
- 1Y return
- +20.13%
- +14.58%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2019
- News (4w)
- 10
- 11
- Recent ratings
- 25
- 11
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Latest ABBV
- AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
- AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form SD filed by AbbVie Inc.
- AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
- FDA Approval for DECNUPAZ issued to ABBVIE INC
- U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
- SEC Form 144 filed by AbbVie Inc.
- AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
- AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
- Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults
Latest PHAT
- Director Parikh Asit received a gift of 28,000 shares and gifted 28,000 shares, decreasing direct ownership by 54% to 24,122 units (SEC Form 4)
- Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
- Director Parikh Asit was granted 24,122 shares and exercised 17,500 shares at a strike of $4.95, increasing direct ownership by 396% to 52,122 units (SEC Form 4)
- Director Fields Heidi was granted 24,122 shares, increasing direct ownership by 80% to 54,122 units (SEC Form 4)
- Director Topper James N was granted 24,122 shares, increasing direct ownership by 57% to 66,718 units (SEC Form 4)
- Director Stenhouse Mark was granted 24,122 shares, increasing direct ownership by 80% to 54,122 units (SEC Form 4)
- Director Schroeder Theodore R was granted 24,122 shares, increasing direct ownership by 115% to 45,122 units (SEC Form 4)
- Director Cola Michael F was granted 24,122 shares, increasing direct ownership by 61% to 63,920 units (SEC Form 4)
- Director Karbe Frank was granted 24,122 shares, increasing direct ownership by 36% to 91,622 units (SEC Form 4)
- SEC Form 8-K filed by Phathom Pharmaceuticals Inc.